IMMX
Immix Biopharma, Inc. NASDAQ Listed Dec 16, 2021$11.24
-2.17%
vs $11.49
Mkt Cap $611.5M
52w Low $1.94
91.2% of range
52w High $12.14
50d MA $9.43
200d MA $7.65
P/E (TTM)
—
EV/EBITDA
—
P/B
4.0x
Debt/Equity
0.0x
ROE
-222.2%
P/FCF
-15.4x
RSI (14)
67.20
ATR (14)
$0.71
Beta
0.21
50d MA
$9.43
200d MA
$7.65
Avg Volume
1.8M
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
11400 West Olympic Boulevard · Los Angeles, CA 90064 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -0.21 | -0.27 | -28.6% | 8.91 | -8.8% | -2.1% | -6.5% | +5.3% | +6.2% | -5.4% | — |
| Nov 7, 2025 | AMC | -0.19 | -0.24 | -26.3% | 3.15 | +3.5% | +2.9% | -0.3% | +15.2% | -3.0% | +16.6% | — |
| Aug 8, 2025 | AMC | -0.21 | -0.22 | -4.8% | 2.39 | +0.0% | -2.9% | -0.9% | +1.3% | -6.0% | +3.7% | — |
| May 8, 2025 | AMC | -0.23 | -0.15 | +34.8% | 2.15 | -2.3% | -2.8% | +0.0% | -5.3% | +0.0% | +5.6% | — |
| Mar 24, 2025 | AMC | -0.25 | -0.16 | +36.0% | 1.82 | +0.0% | +1.6% | -1.1% | -6.6% | -0.6% | -1.2% | — |
| Nov 12, 2024 | AMC | -0.16 | -0.24 | -50.0% | 1.72 | -1.7% | -8.7% | +3.2% | -1.9% | +6.3% | +0.6% | — |
| Aug 12, 2024 | AMC | -0.21 | -0.15 | +28.6% | 1.85 | +0.0% | +0.5% | +2.7% | -1.0% | +0.5% | +10.0% | — |
| May 9, 2024 | AMC | -0.23 | -0.22 | +4.3% | 2.18 | -5.5% | +0.0% | -0.9% | +1.9% | +6.8% | -4.3% | — |
| Mar 29, 2024 | AMC | -0.23 | -0.24 | -4.3% | — | — | — | — | — | — | — | — |
| Nov 9, 2023 | AMC | -0.23 | -0.23 | +0.0% | 3.71 | +0.0% | +12.9% | +1.4% | +3.5% | +1.4% | -0.2% | — |
| Aug 11, 2023 | AMC | -0.17 | -0.24 | -41.2% | 1.82 | -1.1% | +0.5% | +1.6% | -4.8% | -7.9% | +6.1% | — |
| May 12, 2023 | AMC | -0.14 | -0.18 | -28.6% | 2.13 | -1.4% | -3.3% | -10.2% | -4.3% | +7.9% | -14.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 22 | Needham | Initiates | Buy | $21 | $9.57 | $9.78 | +2.2% | -1.7% | -6.5% | -3.2% | +2.0% | -2.9% |
| Jun 18 | BofA Securities | Initiates | Buy | $27 | $9.13 | $9.92 | +8.7% | -4.5% | +7.8% | +5.4% | +1.3% | -3.2% |
| Mar 30 | Mizuho | Maintains | Outperform → Outperform | — | $8.15 | $8.19 | +0.5% | +5.3% | +6.2% | -5.4% | +3.7% | -3.9% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.15 | $8.19 | +0.5% | +5.3% | +6.2% | -5.4% | +3.7% | -3.9% |
| Mar 27 | Citizens | Maintains | Market Outperform → Market Outperform | — | $8.72 | $8.97 | +2.9% | -6.5% | +5.3% | +6.2% | -5.4% | +3.7% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.72 | $8.97 | +2.9% | -6.5% | +5.3% | +6.2% | -5.4% | +3.7% |
| Dec 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.15 | $6.30 | +2.4% | +7.3% | +2.0% | +9.7% | -4.2% | -12.2% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.22 | $2.22 | +0.0% | -5.4% | -0.5% | -4.3% | -2.0% | +6.6% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.11 | $2.07 | -1.9% | -2.4% | +6.3% | +8.2% | -1.3% | +3.0% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.01 | $1.96 | -2.5% | -2.0% | +0.0% | +1.0% | +0.0% | -0.5% |
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.35 | $2.40 | +2.1% | -2.1% | -0.9% | -1.3% | -6.7% | +1.0% |
| Oct 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.46 | $1.48 | +1.4% | -8.2% | +21.6% | -11.0% | +5.5% | +0.7% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.90 | $1.90 | +0.0% | +10.0% | +3.8% | +5.1% | -3.1% | -2.7% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.15 | $2.16 | +0.5% | +4.2% | -5.8% | +6.6% | -8.0% | +0.5% |
| Jul 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.16 | $2.23 | +3.2% | +1.9% | -7.3% | -1.5% | +5.0% | -3.3% |
| Aug 14 | Roth MKM | Maintains | Buy → Buy | — | $1.82 | $1.80 | -1.1% | +0.5% | +1.6% | -4.8% | -7.9% | +6.1% |
| Feb 22 | Roth MKM | Maintains | Buy → Buy | — | $2.07 | $2.30 | +11.1% | +12.1% | -3.4% | -4.0% | -0.5% | -2.8% |
No insider trades available.
8-K · 8.01
!! High
Immix Biopharma, Inc. -- 8-K 8.01: Material Event / Announcement
Immix Biopharma terminated executive Richard Graydon effective July 17, 2026, though management expects minimal business impact given his brief tenure.
Jul 20
8-K
Immix Biopharma, Inc. -- 8-K Filing
May 29
8-K · 8.01
!! High
Immix Biopharma, Inc. -- 8-K 8.01: Material Event / Announcement
May 21
8-K · 8.01
!! High
Immix Biopharma, Inc. -- 8-K 8.01: Material Event / Announcement
May 21
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
IMMX's completed Phase 2 enrollment for its lead AL amyloidosis therapy positions it for Q3 2026 data and potential 2027 commercialization, offering near-term catalyst visibility for this rare disease specialist.
Mar 30
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
IMMX is raising capital through an equity offering with Citizens JMP Securities, which dilutes existing shareholders but provides cash for operations or growth, so investors should monitor the offering size and use of proceeds.
Mar 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Janus Henderson Group Plc | 4,802,002 | $44M | New | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 1,787,994 | $16M | New | Mar 2026 |
| 3 | Millennium Management | 1,750,200 | $16M | Added | Mar 2026 |
| 4 | Marshall Wace, Llp | 1,641,552 | $15M | Reduced | Mar 2026 |
| 5 | Franklin Resources Inc | 969,066 | $9M | Reduced | Mar 2026 |
| 6 | Velan Capital Investment Management Lp | 740,000 | $7M | Added | Mar 2026 |
| 7 | Blue Owl Capital Holdings Lp | 547,552 | $5M | Reduced | Mar 2026 |
| 8 | Susquehanna International Group, Llp | 471,394 | $4M | Added | Mar 2026 |
| 9 | Qube Research & Technologies Ltd | 187,675 | $2M | Added | Mar 2026 |
| 10 | Sei Investments Co | 147,140 | $1M | Added | Mar 2026 |
| 11 | Morgan Stanley | 253,244 | $1M | Added | Dec 2025 |
| 12 | Northern Trust Corp | 138,232 | $1M | Added | Mar 2026 |
| 13 | Informed Momentum Co Llc | 120,856 | $1M | — | Mar 2026 |
| 14 | Jane Street Group, Llc | 167,132 | $874K | Added | Dec 2025 |
| 15 | Tocqueville Asset Management L.p. | 89,550 | $816K | Added | Mar 2026 |
| 16 | Bank Of New York Mellon Corp | 83,611 | $762K | Reduced | Mar 2026 |
| 17 | Ubs Group Ag | 76,832 | $700K | Added | Mar 2026 |
| 18 | Barclays Plc | 51,768 | $472K | Added | Mar 2026 |
| 19 | Citadel Advisors Llc | 47,173 | $430K | Reduced | Mar 2026 |
| 20 | Bank Of America Corp /de/ | 41,131 | $375K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 13
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Franklin Biotechnology Discovery Fund | 357,034 | $2M | Jan 2026 |
| 2 | Timber Point Global Allocations Fund | 120,000 | $1M | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 109,438 | $985K | May 2026 |
| 4 | Fidelity Extended Market Index Fund | 115,751 | $934K | Feb 2026 |
| 5 | Fidelity Series Total Market Index Fund | 88,336 | $795K | May 2026 |
| 6 | iShares Micro-Cap ETF | 86,999 | $793K | Mar 2026 |
| 7 | Ultra-Small Company Fund | 80,000 | $729K | Mar 2026 |
| 8 | LVIP State Street Small-Cap Index Fund | 29,800 | $307K | Jun 2026 |
| 9 | Small Cap Core Fund | 15,008 | $137K | Mar 2026 |
| 10 | Fidelity Nasdaq Composite Index Fund | 16,844 | $136K | Feb 2026 |
| 11 | Small-Cap Index Portfolio | 11,790 | $122K | Jun 2026 |
| 12 | PD Small-Cap Growth Index Portfolio | 3,756 | $39K | Jun 2026 |
| 13 | Victory Extended Market Index Fund | 3,584 | $21K | Jan 2026 |
Valuation
Market Cap
$611.5M
Enterprise Value
$279.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.34x
P/B
3.95x
P/S
—
P/FCF
-15.36x
EV/EBITDA
—
Shares Out
33.0M
Financials (TTM)
Revenue
$0
Net Income
-$35.0M
EBITDA
-$34.6M
Free Cash Flow
-$24.7M
Op Cash Flow
-$23.9M
EPS Basic
$-0.89
EPS Diluted
$-0.92
EPS Forward
$-0.77
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$104.8M
Total Liab.
$11.0M
Total Equity
$93.8M
Cash
$100.4M
LT Debt
$934K
Book Value/Sh
$2.85
Debt/Equity
0.01x
Current Ratio
10.01
Quick Ratio
10.01
Returns & Growth
ROE
-222.2%
ROA
-28.1%
ROIC
-28.7%
Rev Growth YoY
+0.0%
EPS Growth YoY
-17.1%
Price Returns
2W
+36.1%
1M
+3.4%
3M
+7.8%
6M
+54.6%
12M
+399.6%
Technicals
52W High
$12.14
52W Low
$1.94
50d MA
$9.43
200d MA
$7.65
RSI (14)
67.20
ATR (14)
$0.71
Beta
0.21
Avg Volume
1.8M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$14.50
High
$15.00
Low
$14.00
Median
$14.50
Data updated apr 25, 2026 3:18pm
· Source: financialmodelingprep.com